<DOC>
	<DOCNO>NCT02983604</DOCNO>
	<brief_summary>The primary objective Phase 1b Dose Escalation part study characterize safety tolerability GS-5829 combination exemestane fulvestrant woman advance estrogen receptor positive Her2-negative ( ER+/HER2- ) breast cancer determine maximum tolerate dose ( MTD ) ( already determine ) recommend dose Phase 2 part study . The primary objective Randomized Phase 2 Dose Expansion portion study evaluate efficacy GS-5829 combination exemestane fulvestrant compare exemestane fulvestrant alone woman advance ER+/HER2- breast cancer .</brief_summary>
	<brief_title>GS-5829 Combination With Exemestane Fulvestrant Comparing With Exemestane Fulvestrant Alone Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Key Histologically cytologically confirm breast cancer evidence metastatic locally advanced disease amenable resection radiation therapy curative intent progress treatment least one prior hormonal therapy . Note : In refer prior hormonal therapy ; target therapy , palbociclib and/or everolimus investigative targeted therapy administer part prior hormonal therapy regimen allow washout period reach . Phase 1b Dose Escalation Individuals may unlimited prior hormonal therapy total 2 prior chemotherapy regimen ( adjuvant chemotherapy consider 1 regimen ) . Individuals may progress fulvestrant exemestane single agent Randomized Phase 2 Dose Expansion Individuals may unlimited prior hormonal therapy , one adjuvant chemotherapy permit ( prior chemotherapy metastatic disease allow ) . Individuals enrol Group 1 must exemestane naïve individual enrol Group 2 must fulvestrant naïve . If individual naive exemestane fulvestrant , investigator 's decision Group enroll Documentation ER positive ( ≥ 1 % positive stain cell local standard ) base recent tumor biopsy , unless boneonly disease Documented HER2negative tumor base local test recent tumor biopsy ( immunohistochemistry score 0/1+ negative situ hybridization HER2/CP17 ratio &lt; 2 single probe assessment HER2 copy number &lt; 4 ) Postmenopausal individual consider postmenopausal state define one following : Age ≥ 60 year Age &lt; 60 year cessation regular menses least 12 consecutive month absence chemotherapy , tamoxifen , toremifene , ovarian suppression serum estradiol folliclestimulating hormone ( FSH ) level within postmenopausal range Prior bilateral oophorectomy Pre/perimenopausal woman enrol amenable treated luteinizinghormone release hormone ( LHRH ) agonist , goserelin . Individuals must commence treatment goserelin alternative LHRH agonist least 4 week prior first dose study drug . If individual receive alternative LHRH agonist prior study entry , must switch goserelin Cycle 1 Day 1 ( C1D1 ) duration study Measurable disease define per RECIST v. 1.1 , boneonly disease must lytic mixed lytic blastic lesion accurately assess compute tomography ( CT ) magnetic resonance imaging ( MRI ) . Individuals boneonly disease blasticonly metastases eligible All acute toxic effect prior antitumor therapy resolve Grade ≤ 1 start study drug dosing ( exception alopecia [ Grade 1 2 permit ] neurotoxicity [ Grade 1 2 permitted ] ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 1 Life expectancy ≥ 3 month , opinion investigator Adequate organ function define follow : Hematologic : Platelets ≥ 100 x 109/L ; Hemoglobin ≥ 9.0 g/dL ; absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ( without platelet transfusion granulocytic growth factor within previous 7 day hematologic laboratory value obtain screen visit ) Hepatic : aspartate transaminase ( AST ) / alanine transaminase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) ( liver metastasis present , ≤ 5 x ULN ) ; total conjugate bilirubin ≤ 1.5 x ULN Renal : Serum Creatinine ≤ 1.5 x ULN creatinine clearance ( CrCl ) ≥ 60 mL/min calculate CockroftGault method Coagulation : International Normalized Ratio ( INR ) ≤ 1.2 Negative serum pregnancy test Females childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception describe study protocol Females nursing must agree discontinue nurse first dose GS5829 Able willing provide write informed consent participate study Key History evidence clinically significant disorder , condition , disease , opinion investigator Gilead medical monitor would pose risk individual safety interfere study evaluation , procedure , completion Known brain metastasis leptomeningeal disease Uncontrolled intercurrent illness include , limited , active uncontrolled infection , active chronic bleeding event within 28 day prior first dose study drug , uncontrolled cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement judge treat physician Myocardial infarction , symptomatic congestive heart failure ( New York Heart Association Classification &gt; Class II ) , unstable angina , serious uncontrolled cardiac arrhythmia within last 6 month C1D1 Major surgery , define surgical procedure involve general anesthesia significant incision ( i.e. , large require placement central venous access , percutaneous feed tube ) within 28 day first dose study drug Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption GS5829 , include unresolved nausea , vomit , diarrhea Common Terminology Criteria Adverse Events ( CTCAE ) Grade &gt; 1 Minor surgical procedure ( ) within 7 day enrollment randomization , yet recover prior surgery ( placement central venous access device , fine needle aspiration , endoscopic biliary stent ≥ 1 day enrollment randomization acceptable ) History concurrent second malignancy , except : adequately treat local basal cell squamous cell carcinoma skin ; cervical carcinoma situ ; superficial bladder cancer ; adequately treat Stage 1 2 cancer currently complete remission ; cancer complete remission ≥ 5 year Antitumor therapy ( chemotherapy , chemoradiation , radiation , molecular target therapy ) within 21 day 5 halflives whichever longer , study drug dosing ( 6 week nitrosoureas , mitomycin C , molecular agent t1/2 &gt; 10 day ) ; 5 halflives investigational drug ; concurrent use goserelin pre/perimenopausal breast cancer exemestane fulvestrant per protocol permit History long QT syndrome whose corrected QT interval ( QTc ) measure ( Fridericia method ) screen prolong ( &gt; 470 m ) . Individuals screen fail due criterion eligible rescreened Prior exposure bromodomain ( BET ) inhibitor Immunotherapy within 6 month C1D1 Evidence bleed diathesis clinically significant bleeding , within 28 day C1D1 history hemoptysis &gt; 2.5 mL/1 teaspoon within 6 month C1D1 Anticoagulation therapy within 7 day C1D1 , include acetylsalicylic acid , low molecular weight heparin , warfarin Known human immunodeficiency virus ( HIV ) infection Hepatitis B surface Antigen ( HBsAg ) positive Hepatitis C virus ( HCV ) antibody positive HCV RNA positive Use moderate/strong cytochrome P450 ( CYP ) 3A4 inhibitor moderate/strong CYP3A4 inducer within 2 week prior first dose study drug History high grade esophageal gastric varix Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Exemestane</keyword>
	<keyword>Aromasin</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Faslodex</keyword>
	<keyword>Breast Cancer ,</keyword>
	<keyword>HER 2-</keyword>
	<keyword>Estrogen receptor positive</keyword>
</DOC>